Alterity Therapeutics Stock In The News

ATHE Stock  USD 5.40  0.09  1.69%   
Our overall analysis of Alterity Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Alterity Therapeutics. The specific impact of Alterity Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Alterity Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Alterity Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Alterity Therapeutics Backtesting and Alterity Therapeutics Hype Analysis.
For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.

Alterity Therapeutics Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
https://www.globenewswire.com/news-release/2025/07/30/3123940/0/en/Appendix-4C-Q4-FY25-Quarterly-Cash-Flow-Report.html
 Neutral
seekingalpha News
Alterity reports data from multiple system atrophy study
https://seekingalpha.com/news/4472734-alterity-reports-data-from-multiple-system-atrophy-study?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Bullish
Macroaxis News: globenewswire.com
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
https://www.globenewswire.com/news-release/2025/07/28/3122359/0/en/Alterity-Therapeutics-Reports-Positive-Topline-Data-from-Open-Label-Phase-2-Clinical-Trial-of-ATH434-in-Multiple-System-Atrophy.html
 Neutral
Macroaxis News: globenewswire.com
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
https://www.globenewswire.com/news-release/2023/11/27/2786053/0/en/Alterity-Therapeutics-Announces-Presentation-of-Novel-Biomarker-Data-for-Evaluation-of-Multiple-System-Atrophy.html
 Neutral
Macroaxis News: globenewswire.com
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
https://www.globenewswire.com/news-release/2023/11/16/2781730/0/en/Alterity-Therapeutics-Announces-Presentation-of-New-Data-Demonstrating-Novel-Mechanisms-of-ATH434.html
 Neutral
Macroaxis News: globenewswire.com
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
https://www.globenewswire.com/news-release/2023/11/08/2776100/0/en/Alterity-Therapeutics-Completes-Enrolment-in-ATH434-201-Phase-2-Clinical-Trial-in-Multiple-System-Atrophy.html
 Neutral
Macroaxis News: globenewswire.com
Appendix 4C – Q1 FY24 Quarterly Cash Flow Report
https://www.globenewswire.com/news-release/2023/10/30/2769068/0/en/Appendix-4C-Q1-FY24-Quarterly-Cash-Flow-Report.html
 Bullish
Macroaxis News: globenewswire.com
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
https://www.globenewswire.com/news-release/2023/08/31/2735127/0/en/Alterity-Therapeutics-Presents-New-Data-on-Multiple-System-Atrophy-a-Rare-Parkinsonian-Disorder.html
 Neutral
Macroaxis News: globenewswire.com
Alterity Therapeutics Granted New Compos...
https://www.globenewswire.com/news-release/2023/08/23/2730296/0/en/Alterity-Therapeutics-Granted-New-Composition-of-Matter-Patent-in-Europe-for-Neurodegenerative-Diseases-including-Parkinson-s-and-Alzheimer-s.html
 Neutral
Macroaxis News: globenewswire.com
Alterity Therapeutics Rare Disease Natur...
https://www.globenewswire.com/news-release/2023/08/22/2729364/0/en/Alterity-Therapeutics-Rare-Disease-Natural-History-Study-to-be-Featured-at-the-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html
 Neutral

Alterity Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Alterity and other traded companies coverage with news coverage. We help investors stay connected with Alterity headlines for the 9th of August to make an informed investment decision based on correlating the impacts of news items on Alterity Stock performance. Please note that trading solely based on the Alterity Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Alterity Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Alterity Therapeutics investors visualize upcoming and past events in order to time the market based on Alterity Therapeutics noise-free hype analysis.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alterity Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alterity Therapeutics' short interest history, or implied volatility extrapolated from Alterity Therapeutics options trading.
When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports:
Check out Alterity Therapeutics Backtesting and Alterity Therapeutics Hype Analysis.
For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.36)
Revenue Per Share
0.6
Quarterly Revenue Growth
(0.15)
Return On Assets
(0.78)
Return On Equity
(1.56)
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.